FeesSafety
Pluang+

Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Market News
22 Nov 2026, 15:05 WIB
The Motley Fool
View Source
Neutral
Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson and Pfizer, two healthcare giants, are taking different growth paths heading into 2027. Johnson & Johnson maintains a balanced business with strong pharmaceutical and medical device segments, showing steady revenue growth and a solid dividend history. Pfizer is focusing on oncology and obesity treatments to drive future growth but faces challenges like legal risks and integration of acquisitions. Despite Pfizer's higher dividend yield, Johnson & Johnson's stability and larger dividend payout make it the preferred choice for long-term investors in 2027.

As of Nov 22, 2026 20:02 WIB, Johnson & Johnson trades at USD 270.47 with a 1.98% dividend yield on Pluang. Pfizer is priced at USD 27.40 and offers a higher dividend yield of 6.28%. Despite Pfizer's higher yield, Johnson & Johnson sees more buy interest on Pluang, with 96% of orders to buy compared to Pfizer's 100% buy activity but lower price and market cap.

More News (JNJ)

Dow drops nearly 950 points into correction as tech sell-off spreads and Fed rate hike looms

Dow drops nearly 950 points into correction as tech sell-off spreads and Fed rate hike looms

The Dow Jones Industrial Average fell nearly 950 points on Friday, entering correction territory by closing over 10% below its record high. The sell-off was driven by continued weakness in technology stocks, including a 14% drop in Nvidia after SEC a...

Bearish
8 hours ago
Dividend Aristocrats in Roth IRAs offer tax-free dividends and no required minimum distributions.

Dividend Aristocrats in Roth IRAs offer tax-free dividends and no required minimum distributions.

Dividend Aristocrats are S&P 500 companies with 25+ years of dividend increases, like Coca-Cola, Procter & Gamble, and Johnson & Johnson. Holding them in a Roth IRA shelters dividends from taxes, unlike taxable accounts where dividends face 15% or hi...

Bullish
1 day ago
TREMFYA shows significant improvement in spinal pain and inflammation in psoriatic arthritis patients in Phase 4 study

TREMFYA shows significant improvement in spinal pain and inflammation in psoriatic arthritis patients in Phase 4 study

Johnson & Johnson's TREMFYA (guselkumab) demonstrated significant improvements in spinal pain, stiffness, and MRI-confirmed inflammation in patients with axial psoriatic arthritis (PsA) in the Phase 4 STAR study. The study, the first of its kind usin...

Company Fundamentals
Bullish
2 days ago
5 reliable dividend stocks keep raising payouts yearly for steady passive income growth.

5 reliable dividend stocks keep raising payouts yearly for steady passive income growth.

This article highlights five U.S.-listed companies—Johnson & Johnson, Procter & Gamble, Coca-Cola, Automatic Data Processing, and Lowe's—that have a strong track record of increasing dividends annually. These companies maintain dividend safety by pay...

Market News
Bullish
2 days ago
Johnson & Johnson's new prostate cancer drug shows 75% response in early trials, boosting its strong pipeline.

Johnson & Johnson's new prostate cancer drug shows 75% response in early trials, boosting its strong pipeline.

Johnson & Johnson's investigational drug JNJ-6143, acquired through a $3.05 billion purchase of Halda Therapeutics, demonstrated a 75% overall response rate in a Phase 1 trial for metastatic castration-resistant prostate cancer. This promising early ...

Market News
Bullish
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App